These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24205725)

  • 21. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease.
    Tuyama AC; Chang CY
    J Diabetes; 2012 Sep; 4(3):266-80. PubMed ID: 22564417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.
    Gambino R; Musso G; Cassader M
    Antioxid Redox Signal; 2011 Sep; 15(5):1325-65. PubMed ID: 20969475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index.
    Wang Z; Xu M; Hu Z; Shrestha UK
    Menopause; 2015 Jun; 22(6):667-73. PubMed ID: 25513983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load.
    Gambino R; Bugianesi E; Rosso C; Mezzabotta L; Pinach S; Alemanno N; Saba F; Cassader M
    Int J Mol Sci; 2016 Mar; 17(4):479. PubMed ID: 27043543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I.
    Arturi F; Succurro E; Procopio C; Pedace E; Mannino GC; Lugarà M; Procopio T; Andreozzi F; Sciacqua A; Hribal ML; Perticone F; Sesti G
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1640-4. PubMed ID: 21816784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of liver disease in Korea: nonalcoholic fatty liver disease.
    Park SH
    Korean J Hepatol; 2009 Dec; 15 Suppl 6():S34-9. PubMed ID: 20037278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors.
    Koller T; Kollerova J; Hlavaty T; Huorka M; Payer J
    Scand J Gastroenterol; 2012 Feb; 47(2):197-203. PubMed ID: 22182015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways.
    Weiss TS; Lupke M; Ibrahim S; Buechler C; Lorenz J; Ruemmele P; Hofmann U; Melter M; Dayoub R
    PLoS One; 2017; 12(9):e0184282. PubMed ID: 28877220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-alcoholic steatohepatitis - from NAFLD to MAFLD].
    Balmer ML; Dufour JF
    Ther Umsch; 2011 Apr; 68(4):183-8. PubMed ID: 21452138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
    Marchesini G; Bugianesi E; Forlani G; Cerrelli F; Lenzi M; Manini R; Natale S; Vanni E; Villanova N; Melchionda N; Rizzetto M
    Hepatology; 2003 Apr; 37(4):917-23. PubMed ID: 12668987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic syndrome and NASH.
    Marchesini G; Marzocchi R
    Clin Liver Dis; 2007 Feb; 11(1):105-17, ix. PubMed ID: 17544974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.